Dorsey Wright & Associates Acquires New Stake in Gilead Sciences, Inc. $GILD

Dorsey Wright & Associates acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 9,474 shares of the biopharmaceutical company’s stock, valued at approximately $1,320,000.

Other large investors have also recently added to or reduced their stakes in the company. Paulson Wealth Management Inc. raised its stake in shares of Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the period. Essex Financial Services Inc. boosted its position in shares of Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after buying an additional 71 shares during the period. Davidson Trust Co. boosted its position in shares of Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 74 shares during the period. Alpha Cubed Investments LLC grew its holdings in shares of Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares in the last quarter. Finally, Personal CFO Solutions LLC raised its position in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after buying an additional 76 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,000 shares of company stock valued at $9,978,740 in the last quarter. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on GILD. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Royal Bank Of Canada reduced their target price on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research report on Monday, July 6th. Finally, Rothschild & Co Redburn cut their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Twenty-six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $159.04.

Gilead Sciences Trading Down 1.5%

Shares of Gilead Sciences stock opened at $134.28 on Friday. The stock has a market cap of $166.72 billion, a P/E ratio of 18.29 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12-month low of $107.75 and a 12-month high of $157.29. The business’s 50 day moving average is $129.73 and its 200-day moving average is $135.22.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the business earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.